| | english | español | français |
Go to record ID

  Home|Finding Information|Record details   Printer-friendly version

Modified Organism
Poulvac® ST vaccine
Record information and status
Record ID
105185
Status
Published
Date of creation
2014-01-15 19:18 UTC (gutemberg.sousa@mctic.gov.br)
Date of publication
2014-01-16 17:18 UTC (dina.abdelhakim@cbd.int)

Living Modified Organism identity
The image below identifies the LMO through its unique identifier, trade name and a link to this page of the BCH. Click on it to download a larger image on your computer. For help on how to use it go to the LMO quick-links page.

LMO name
Poulvac® ST vaccine
Transformation event
STM-1
Developer(s)
Dr Matusalem Pereira Santos
President Of CIBio
Zoetis Indústria de Produtos Veterinários Ltda
Fort Dodge Saúde Animal
Rua Luis Fernando Rodriguez, 1701 Vila Boa Vista
Campinas, São Paulo
Brazil, 13064798
Phone:+55 19 37456240
Fax:+55 19 37456189
Email:elianaaguiar@cdn.com.br
Url:Zoetis Indústria de Produtos Veterinários
Description
Poulvac ST modified-live vaccine aids in the reduction of Salmonella enteritidis, Salmonella heidelberg and Salmonella typhimurium colonization
Recipient Organism or Parental Organisms
The term Recipient organism refers to an organism (either already modified or non-modified) that was subjected to genetic modification, whereas Parental organisms refers to those that were involved in cross breeding or cell fusion.
Salmonella typhimurium - SALTM
Point of collection or acquisition of the recipient organism
The receipient organism was isolated from a poultry virulent form of Salmonella typhimurium, strain 82/6915, which was isolated from a chicken in Victoria, Australia in 1982
Characteristics of the transformation process
Vector
Enterobacteria phage P22
Techniques used for the modification
  • Bacteriophage Transduction
Introduced or modified genetic elements
Some of these genetic elements may be present as fragments or truncated forms. Please see notes below, where applicable.
5-enolpyruvylshikimate-3-phosphate synthase gene - Salmonella typhimurium - SALTM
Changes in quality and/or metabolite content - Protein and amino acids
Phosphoserine aminotransferase gene - Salmonella typhimurium - SALTM
Changes in quality and/or metabolite content - Protein and amino acids
Notes regarding the genetic elements introduced or modified in this LMO
The genetic modification of the poultry virulent form of S. typhimurium strain 82/6915, was performed using enterobacteria phage P22 transduction of a DNA vector containing the S. typhimurium LT2 aroA554::Tn10 transposon originating from strain 1545.

The insertion site of the transposon Tn10 is in the aroA-serC operon. aroA specifies the enzyme 3-enolpyruvylshikimate-5-phosphate synthetase. Strains contining this transposon cannot grow on chemically defined media unless provided with the essential metabolites derived from chorismic acid, i.e. the aromatic amino acids tyrosine, phenylalanine, and tryptophan and two minor aromatic metabolites, p-aminobenzoate, needed as a precursor of folic acid, and 2,3-dihydroxybenzoic acid, as a precursor of the iron-chelating compound enterobactin (enterochelin). serC encodes phosphoserine aminotransferase, an enzyme in the biosynthesis of serine. Insertion of the transposon also imparts tetracycline resistance.

Transduction of the receipient strain S. typhimurium 82/6915 was carried out in the presence of tetracycline supplemented medium.  Transductant clones that were found to be resistant to tetracycline were selected.

Colonies were isolated and further screened for loss of tetracycline resistance. The isolation of tetracycline-sensitive variants is facilitated by the fact that tetracycline, at appropriate concentrations, prevents multiplication of tetracycline-sensitive bacteria, but does not kill them, whereas penicillin kills multiplying bacteria but spares non-multiplying bacteria. The technique of penicillin-selection was used for isolation of tetracycline-sensitive variants.

A tetracycline-sensitive mutant that remained auxotrophic for aromatic metabolites and serine was identified. The resulting S. typhimurium strain 82/6915 aroA-serC deletion mutant, was denominated as strain STM-1.

The requirement for aromatic metabolites and serine,is not met when S. typhimurium is present in vertebrate tissues, resulting in retardation of growth in vivo or outside the host. Deficient lineages of this modified-live vaccine remain in host tissue for several days, but without causing symptoms and eventually be eliminated by immunological defence mechanisms while still imparting protection against salmonella.
LMO characteristics
Modified traits
Common use(s)
  • Vaccine

Records referencing this document (4)
IDDescription
4record(s) found
Country's Decision or any other Communication2 records
Risk Assessment2 records